Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
Back to event

Early-Phase IND Protocol Recommendations for Solid Tumors; Draft Guidance for Industry; Availability

By Drug Administration, Human Services Department, Food, Health · Nov 11, 2026, 11:00 PM CST

Read full article at Federal Register
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry titled "Early-Phase IND Protocol Recommendations for Solid Tumors." The purpose of this draft guidance is to provide recommendations to sponsors and clinical investigators developing early-phase trials, which include first-in- human (FIH) protocols or protocols for drugs and biologic pr

Excerpt shown under fair-use limits. Full text remains with the original publisher.

People in this coverage

Explore their history and attributable record. Being mentioned does not imply endorsement.

Layer 1 · Claims & fact checks

AI analysis

Layer 2 · Biblical perspective

Biblical interpretation
INSUFFICIENT CONTEXT
Read the biblical analysis

Layer 3 · Reporting analysis

AI analysis

Official announcementThe language is formal and authoritative, typical of a regulatory agency communicating a new policy document.

Scope clarificationThe statement delineates the boundaries of the guidance, limiting its applicability and preemptively addressing potential misunderstandings.

Context

AI analysis

Missing context

The announcement does not explain how the draft guidance will affect ongoing or future trial designs, the timeline for public comment, or any potential regulatory implications for sponsors.

Important context

The guidance is a draft, meaning it is open for public comment before finalization, and it is limited to solid‑tumor indications, excluding hematologic malignancies.

Opinion vs. reporting

AI analysis

The text is purely factual reporting of an FDA announcement; it contains no opinion or editorial commentary.